• 简体中文
  • English
登录 注册
当前位置: 首页 > 药物分子靶点数据库 反馈纠错 帮助中心

一个药物有多个靶点,靶点与靶点采用分号隔开

导出数据
药物名称 分子靶点 ATC编码 适应症
N-Octyl-2-Hydroxyethyl Sulfoxide Ferrichrome-iron receptor;Colicin I receptor;Outer membrane porin C
Oxyphenisatin A06AB01
(2R)-2-({6-[benzyl(methyl)amino]-9-isopropyl-9H-purin-2-yl}amino)butan-1-ol Pyridoxal kinase
Blinatumomab B-lymphocyte antigen CD19;T-cell surface glycoprotein CD3 delta chain L01XC19 Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Elosulfase alfa A16AB12 Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
Metreleptin Leptin receptor Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Dulaglutide Glucagon-like peptide 1 receptor A10BX14 Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Albiglutide Glucagon-like peptide 1 receptor A10BX13 Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Pembrolizumab Programmed cell death protein 1 L01XC18 Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:  patients with unresectable or metastatic melanoma.  patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.  patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.  patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Siltuximab Interleukin-6 L04AC11 Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
Nivolumab Programmed cell death protein 1 L01XC17 Nivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
Vedolizumab Integrin alpha-4;Integrin beta-7 L04AA33 Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
Secukinumab Interleukin-17A L04AC10 For the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
Obinutuzumab B-lymphocyte antigen CD20 L01XC15 Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
Certolizumab pegol Tumor necrosis factor L04AB05 Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
Raxibacumab Protective antigen J06BB18 Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Teduglutide Glucagon-like peptide 2 receptor A16AX08 Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
Glucarpidase V03AF09 Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (> 1 micromole per liter).
Ocriplasmin Fibronectin;Alpha-2-macroglobulin;Alpha-2-antiplasmin S01XA22 Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
Asparaginase Erwinia chrysanthemi Asparaginase Erwinia chryanthemi is for the treatment of patients with acute lymphoblastic leukemia (ALL) that have developed a hypersensitivity to Escherichia coli-derivied asparaginase. It is a component of a multi-agent chemotherpeutic regimen for the treatment of the aforementioned disease and is considered second- or third- line treatment in European and American protocols.